Clinical Trials Logo

Hepatic Impairment clinical trials

View clinical trials related to Hepatic Impairment.

Filter by:

NCT ID: NCT06179368 Recruiting - Hepatic Impairment Clinical Trials

Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome

Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

Liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (T4) to triiodothyronine (T3) by Type 1 deiodinase.

NCT ID: NCT06161259 Completed - Hepatic Impairment Clinical Trials

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment

Start date: September 14, 2023
Phase: Phase 1
Study type: Interventional

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of Leritrelvir(RAY1216)

NCT ID: NCT06126575 Not yet recruiting - Hepatic Impairment Clinical Trials

A Pharmacokinetic Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

Start date: January 24, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multi-center, open-label, non-randomized, parallel group study to evaluate the effect of severe hepatic impairment on the PK, safety and tolerability of a single oral dose of Elacestrant.

NCT ID: NCT06094725 Completed - Hepatic Impairment Clinical Trials

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Start date: January 6, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this multiple-dose, adaptive design study is to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of relacorilant relative to healthy matched control male and female subjects (Part 1).

NCT ID: NCT06084104 Recruiting - Hepatic Impairment Clinical Trials

DZD9008 PK Study in Hepatic Impairment Subjects

Start date: October 17, 2023
Phase: Phase 1
Study type: Interventional

This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function

NCT ID: NCT06052566 Recruiting - Hepatic Impairment Clinical Trials

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Start date: November 21, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.

NCT ID: NCT06048302 Recruiting - Healthy Clinical Trials

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Start date: November 30, 2023
Phase: Phase 1
Study type: Interventional

To investigate the safety and pharmacokinetics in patients with moderate hepatic impairment compared to healthy participants after a single oral dose of obicetrapib (10 mg).

NCT ID: NCT06004934 Completed - Hepatic Impairment Clinical Trials

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

Start date: April 17, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this study will be to evaluate the pharmacokinetic properties of avacopan and its metabolite CCX168-M1 after a single oral dose of 30 mg avacopan in participants with mild or moderate hepatic impairment compared to matched healthy controls.

NCT ID: NCT05976321 Recruiting - Healthy Volunteers Clinical Trials

A Study of TAK-279 in Adults With or Without Liver Damage

Start date: September 22, 2023
Phase: Phase 1
Study type: Interventional

The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to participants without liver problems. Other aims are to check for side effects from TAK-279 and to learn how well participants tolerate 1 dose of TAK-279. The participants will need to stay at the clinic for 11 days.

NCT ID: NCT05935033 Recruiting - Hepatic Impairment Clinical Trials

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Start date: June 30, 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to assess the effect of hepatic impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe hepatic impairment relative to matched participants with normal hepatic function.